Obsidian Therapeutics (NASDAQ:OBX) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Obsidian Therapeutics (NASDAQ:OBX) to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently commented on OBX. Piper Sandler assumed coverage on shares of Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 target price for the company. William Blair began coverage on shares of Obsidian Therapeutics in a report on Wednesday, September 9th. They set an “outperform” rating for the company. Lifesci Capital started coverage on shares of Obsidian Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price target for the company. TD Cowen initiated coverage on shares of Obsidian Therapeutics in a research report on Thursday, August 6th. They issued a “buy” rating for the company. Finally, Weiss Ratings started coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They issued a “sell (d-)” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.50.

Obsidian Therapeutics Trading Up 1.4%

Obsidian Therapeutics stock opened at $17.75 on Friday. Obsidian Therapeutics has a 12 month low of $14.57 and a 12 month high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.